gpt-dict.com

番紅花 Saffron × 憂鬱症

結論：證據支持但有警示

L11 明確建議 publish_with_warning — honor L11 recommendation (B10 fix)

B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🧪 反證據已標記 🇹🇼 台灣在地警示

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.68
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
76%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）

各層「支持此療效」的程度

分數越低＝該層越不支持
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.58
L3 機轉生理合理性
0.65
L11 AI 複核獨立判讀
0.65
L2 PubMed原始文獻
0.85
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.678
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis
PMID: 31135916 2019 統合分析 n = 1,869
結論：Saffron produced a large, statistically significant reduction in depressive symptoms vs placebo (SMD = -0.99, 95% CI -1.30 to -0.68, p<0.001, I2=87%). Versus active antidepressants (fluoxetine, citalopram, imipramine), saffron was non-inferior with no significant difference in efficacy (SMD = 0.10, 95% CI -0.10 to 0.30). Anxiety symptom reduction also significant (SMD = -0.95). Heterogeneity was high; effect attenuated but remained significant in sensitivity analyses excluding small or industry-funded trials.
學術資助 效應量：[object Object]
前往 PubMed
Saffron (Crocus sativus L.) in the treatment of mild-to-moderate depression: A randomized, placebo-controlled, double-blind clinical trial
PMID: 31602695 2020 RCT (double-blind) n = 56
結論：Saffron 30 mg/day produced significantly greater reduction in HAM-D scores vs placebo at week 6 (mean change saffron -10.2 vs placebo -4.1, between-group p<0.001). Response rate (>=50% HAM-D reduction) 65% in saffron arm vs 21% placebo. Adverse events (mild GI, headache) did not differ from placebo. Confirms standard 30 mg/day clinical dose used across the Iranian saffron trial program.
學術資助 效應量：[object Object]
前往 PubMed
Saffron versus fluoxetine for the treatment of depression: a systematic review and meta-analysis of randomized controlled trials
PMID: 32392485 2020 統合分析 n = 367
結論：Head-to-head pooled analysis showed no significant difference between saffron 30 mg/day and fluoxetine 20-40 mg/day on depression severity (SMD = 0.01, 95% CI -0.20 to 0.21, p=0.95). Response rates equivalent (RR = 1.04, 95% CI 0.91-1.18). Saffron had significantly fewer adverse events than fluoxetine, particularly sexual dysfunction (RR = 0.30, 95% CI 0.13-0.66) and dry mouth. Authors conclude saffron is non-inferior to fluoxetine for mild-to-moderate MDD with a more favorable tolerability profile.
學術資助 效應量：[object Object]
前往 PubMed
Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials
PMID: 29849461 2018 統合分析 n = 908
結論：Pooled WMD = -6.05 (95% CI -8.27 to -3.83, p<0.001) for depression rating-scale scores, favoring saffron over placebo. Subgroup analyses showed effect was robust across MDD, mild depression, and comorbid populations (post-MI, postpartum, breast-cancer). Funnel plot suggested some publication bias; trim-and-fill adjusted estimate remained significant. Authors conclude saffron is effective as monotherapy and adjunct in adult depression but flag dominance of single-region (Iranian) trials.
學術資助 效應量：[object Object]
前往 PubMed
Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study
PMID: 31475623 2019 RCT (double-blind) n = 73
結論：Saffron augmentation produced significantly greater reduction in MADRS (mean change saffron -14.8 vs placebo -7.2, between-group p<0.001) and HAM-D (-12.1 vs -5.9, p<0.001) at 8 weeks compared to placebo augmentation. Response rate (>=50% reduction) 71% saffron vs 31% placebo. Suggests saffron provides additive benefit on top of standard SSRI therapy in partial responders, supporting its role as augmentation strategy.
學術資助 效應量：[object Object]
前往 PubMed
Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials
PMID: 38913392 2025 Network Meta-analysis n = 4,129
結論：In the network meta-analysis ranking, saffron was among the top three interventions for depression severity reduction, with SMD vs placebo = -1.23 (95% CrI -1.73 to -0.74). Saffron was statistically comparable to fluoxetine, sertraline, and citalopram on efficacy (no significant differences in pairwise SMD). Acceptability (dropout) for saffron was equivalent to placebo and superior to several SSRIs. Authors flag risk-of-bias concerns and dominance of single-country trials but rank saffron as a credible alternative for mild-to-moderate MDD.
學術資助 效應量：[object Object]
前往 PubMed

L4a US FDA
謹慎
Saffron (Crocus sativus L.); CAS 977051-90-3; 21 CFR 73.500, 182.10; COLOR OR COLORING ADJUNCT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT. 來源↗
L4b EU EFSA
反對
a cause and effect relationship has not been established 來源↗
L4c UK NHS
中性
— 本適應症無對應資料
L4d TW TFDA / 衛福部
謹慎
番紅花（Crocus sativus L.）之柱頭可供食品使用 來源↗
L4e WHO
中性
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
謹慎
limited research suggests it may help with mild to moderate depression 來源↗
L5c Cleveland Clinic
支持
Saffron could become a future depression treatment if we get more evidence and data. 來源↗
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽

台灣社群幾乎沒有針對「番紅花 for 憂鬱症」的原生鄉民實測討論：PTT 憂鬱相關板（prozac/mood/WomenTalk）討論集中在處方抗憂鬱藥與病程心情，未把番紅花當主題；regimen 板與番紅花相關的少量心得偏向『助眠』而非憂鬱；Mobile01 藏紅花串多 403 且談料理與真偽辨識。搜尋結果幾乎全被營養師部落格、保健品廠商、線上看診與中醫診所等業配／affiliate 內容佔據，真實匿名使用經驗稀少，無法形成社群共識。

💬社群實感

無共識（針對憂鬱症的原生鄉民實測樣本近乎為零；少量相關心得集中在助眠／舒壓，非憂鬱症本身）

破解迷思 社群最常見的 5 個誤解
✓
事實把『助眠／舒壓』效果直接等同於『治療憂鬱症』療效（社群與業配內容多落在睡眠面向，憂鬱症屬臨床診斷，不能憑保健品自療）
✓
事實誤以為番紅花保健食品可取代抗憂鬱處方藥（SSRI/SNRI），實則專業內容與證據皆不支持，併用前須諮詢醫師、有血清素過量疑慮）
✓
事實誤以為躁鬱症（雙相情緒障礙）也適用番紅花，實際應避免，可能誘發躁期
✓
事實誤以為料理用番紅花香料劑量即等同臨床研究劑量，社群常把香料與標準化萃取 Affron 28-30mg 混為一談，劑量差距極大
✓
事實誤把搜尋到的『營養師／藥師推薦文』當成中立鄉民實測心得，實際多為保健品 affiliate／業配內容
🩹 社群通報的副作用
  • 口乾
  • 頭暈、嗜睡
  • 噁心、食慾改變
  • 頭痛
  • （針對憂鬱症情境的原生副作用反饋稀少，以上為番紅花一般性反饋與業配衛教轉述）
🏷️ 社群熱議品牌

依論壇被提及頻率，非銷售或品質排序。

  • Affron（西班牙專利標準化番紅花萃取，業配與保健品文最常被點名的關鍵成分，非憂鬱症專屬討論）
  • California Gold Nutrition Saffron Extract with Affron 28mg（iHerb 常見規格，社群討論偏助眠脈絡）

⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

伊朗番紅花花絲 1g

代表來源 ↗
L10b · TFDA 法定身份 官方認定

本品為鳶尾科植物番紅花

來源 ↗

  • 心理治療（CBT／人際治療）
  • 抗憂鬱藥物（SSRI 等）
  • 規律運動

i ihealthy.com.tw
番紅花萃取物能改善情緒？唯一獲「Primary」評級的情緒保健品解析
知識科普 2026-05-07
✓ PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v30 engine_version: v1.0 claim_id: CLM-COND-depression-INT-saffron-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-depression-INT-saffron-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "番紅花能改善憂鬱症",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}